WeightWatchers' stock has taken a beating with the rise of breakthrough dieting drugs — but the company can still profit from members who are “puking
Lisa Fickenscher is a business journalist with a wide range of expertise, having covered topics such as food, personal finance, and now the retail business for The New York Post. Her work has also appeared in MarketWatch, Sky News Australia, and Wine Business Monthly. Lisa's articles often focus on the retail industry, including stories on luxury brands, regulatory probes, and the impact of current events on businesses. She can be contacted at [email protected].